Abstract
The accumulation of sphingolipids, including sphingomyelin and glycosphingolipids, in atherosclerotic lesions is well known. Plasma sphingomyelin concentration is correlated with atherosclerosis development and is an independent predictor of coronary artery disease. Similarly, plasma glycosphingolipid levels are increased in conditions associated with atherosclerosis risk. Recent studies have focused on understanding the mechanisms by which specific intermediates and end-products of the sphingolipid biosynthetic pathway, such as sphingomyelin, glycosphingolipids, ceramide and sphingosine-1-phosphate may modulate vascular biology and atherosclerosis. Here we focus on recent work indicating that pharmacological modulation of the sphingolipid biosynthetic pathway could offer a novel treatment for atherosclerosis or, at the very least, provide mechanistic insights concerning the eitiology of this disease which is the major cause of death in developed countries.
Keywords: Atherosclerosis, sphingomyelin, glycosphingolipids, ceramide kinase, ceramide-1-phosphate, myriocin, sphingolipid, inhibitors, ABCA-1
Current Vascular Pharmacology
Title: Fine Tuning Therapeutic Targeting of the Sphingolipid Biosynthetic Pathway to Treat Atherosclerosis
Volume: 4 Issue: 2
Author(s): W. S. Kim, Charles E. Chalfant and Brett Garner
Affiliation:
- Prince of Wales MedicalResearch Institute, Randwick, NSW 2031, Australia.,Australia
Keywords: Atherosclerosis, sphingomyelin, glycosphingolipids, ceramide kinase, ceramide-1-phosphate, myriocin, sphingolipid, inhibitors, ABCA-1
Abstract: The accumulation of sphingolipids, including sphingomyelin and glycosphingolipids, in atherosclerotic lesions is well known. Plasma sphingomyelin concentration is correlated with atherosclerosis development and is an independent predictor of coronary artery disease. Similarly, plasma glycosphingolipid levels are increased in conditions associated with atherosclerosis risk. Recent studies have focused on understanding the mechanisms by which specific intermediates and end-products of the sphingolipid biosynthetic pathway, such as sphingomyelin, glycosphingolipids, ceramide and sphingosine-1-phosphate may modulate vascular biology and atherosclerosis. Here we focus on recent work indicating that pharmacological modulation of the sphingolipid biosynthetic pathway could offer a novel treatment for atherosclerosis or, at the very least, provide mechanistic insights concerning the eitiology of this disease which is the major cause of death in developed countries.
Export Options
About this article
Cite this article as:
Kim S. W., Chalfant E. Charles and Garner Brett, Fine Tuning Therapeutic Targeting of the Sphingolipid Biosynthetic Pathway to Treat Atherosclerosis, Current Vascular Pharmacology 2006; 4(2) . https://dx.doi.org/10.2174/157016106776359844
DOI https://dx.doi.org/10.2174/157016106776359844 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Endothelial Dysfunction, Obesity and Insulin Resistance
Current Vascular Pharmacology Purinergic Signalling and Endothelium
Current Vascular Pharmacology Vitamin, Mineral, and Drug Absorption Following Bariatric Surgery
Current Drug Metabolism Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Obesity- An Adverse Factor in Reproductive Age
Applied Clinical Research, Clinical Trials and Regulatory Affairs (Discontinued) Chymase Inhibitor As a Novel Therapeutic Strategy for Anti-Vascular Remodeling
Vascular Disease Prevention (Discontinued) Renin--Angiotensin System Gene Polymorphism and Regression of Left Ventricular Hypertrophy in Hypertension
Current Pharmacogenomics Macrophage-Derived Foam Cells in Atherosclerosis: Lessons from Murine Models and Implications for Therapy
Current Drug Targets Not Only a Clinical Nightmare: Amniotic Fluid Embolism in Court
Current Pharmaceutical Biotechnology Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical Based Evidence
Current Pharmaceutical Design Endothelins Role in the Control of the Acute Phase of Trypanosoma cruzi Infection
Mini-Reviews in Medicinal Chemistry Therapeutic Modulation of Growth Factors and Cytokines in Regenerative Medicine
Current Pharmaceutical Design Atheroma Burden and Morphology in Women
Current Pharmaceutical Design Microscopies at the Nanoscale for Nano-Scale Drug Delivery Systems
Current Drug Targets Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening Antegrade Techniques for Chronic Total Occlusions
Current Cardiology Reviews Fetal Alcohol Syndrome: A Cautionary Note
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Vascular Pharmacology